Analyst David Li of Bank of America Securities reiterated a Buy rating on BeOne Medicines, boosting the price target to $350.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
David Li has given his Buy rating due to a combination of factors including BeOne Medicines’ strong financial performance and strategic positioning. The company reported significant year-over-year revenue growth in the second quarter of 2025, driven by robust sales of Brukinsa in the US and EU markets. This growth was accompanied by an increase in gross profit margin, reflecting improved operational efficiency and a favorable product mix.
Furthermore, BeOne Medicines has shown a remarkable turnaround from a net loss to a net profit, underscoring its effective cost management and operational execution. The company’s leadership position in the US market and its expansion in the EU have led to an upward revision of its full-year revenue guidance. Additionally, upcoming catalysts such as key clinical trial readouts and potential regulatory filings are expected to bolster its growth trajectory, justifying the raised price objective and Buy rating.
In another report released yesterday, Guggenheim also maintained a Buy rating on the stock with a $365.00 price target.